Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma
DOI:
https://doi.org/10.2340/00015555-3746Keywords:
primary cutaneous B-cell lymphoma, intravenous rituximab therapy, primary cutaneous marginal zone lymphoma, primary cutaneous follicle centre lymphoma, follow-upAbstract
Systemic monotherapy with rituximab is a well-known treatment approach for primary cutaneous follicle centre lymphoma and primary cutaneous marginal zone lymphoma. Both have excellent prognosis despite high relapse rates. To investigate the long-term effectiveness and clinical outcome of intravenous rituximab at a dose of 375 mg/m2 once weekly, data for 26 patients (17 primary cutaneous follicle centre lymphoma and 9 primary cutaneous marginal zone lymphoma) were analysed retrospectively. Complete remissions occurred in 20 (77%) and partial remissions in 6 patients (23%), demonstrating an overall response rate of 100%. The relapse rate was 52.9% in primary cutaneous follicle centre lymphoma and 88.9% in primary cutaneous marginal zone lymphoma. Ongoing complete remissions after therapy with rituximab were observed in 9 patients (34.6%) with a median progression-free survival of 161 months (13.4 years). These results confirm that intravenous rituximab is an effective and well-tolerated treatment with durable responses in a relevant percentage of patients at a median follow-up of 148 months (12.3 years).
Downloads
References
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.
DOI: https://doi.org/10.1182/blood-2016-01-643569
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.
DOI: https://doi.org/10.1182/blood-2018-11-881268
Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24: 1376-1382.
DOI: https://doi.org/10.1200/JCO.2005.03.6285
Bogle MA, Riddle CC, Triana EM, Jones D, Duvic M. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 2005; 53: 479-484.
DOI: https://doi.org/10.1016/j.jaad.2005.04.043
Wilcox RA. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2018; 93: 1427-1430.
DOI: https://doi.org/10.1002/ajh.25224
Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019; 180: 496-526.
DOI: https://doi.org/10.1111/bjd.17240
Errante D, Bernardi D, Bianco A, De Nardi S, Salvagno L. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol 2006; 17: 1720-1721.
DOI: https://doi.org/10.1093/annonc/mdl113
Seker M, Ustaalioglu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, et al. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma. Leuk Res 2010; 34: e160-163.
DOI: https://doi.org/10.1016/j.leukres.2010.02.013
Brandenburg A, Humme D, Terhorst D, Gellrich S, Sterry W, Beyer M. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas. Br J Dermatol 2013; 169: 1126-1132.
DOI: https://doi.org/10.1111/bjd.12484
Fernandez-Guarino M, Ortiz-Romero PL, Fernandez-Misa R, Montalban C. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. Actas Dermosifiliogr 2014; 105: 438-445.
DOI: https://doi.org/10.1016/j.adengl.2014.04.001
Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52: 847-853.
DOI: https://doi.org/10.1016/j.jaad.2005.01.093
Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. Br J Dermatol 2005; 153: 167-173.
DOI: https://doi.org/10.1111/j.1365-2133.2005.06659.x
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk lymphoma 2006; 47: 1902-1907.
DOI: https://doi.org/10.1080/10428190600688099
Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
DOI: https://doi.org/10.1002/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H
Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006; 155: 1197-1200.
DOI: https://doi.org/10.1111/j.1365-2133.2006.07523.x
Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 2008; 59: 953-957.
DOI: https://doi.org/10.1016/j.jaad.2008.08.005
Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009; 20: 326-330.
DOI: https://doi.org/10.1093/annonc/mdn636
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
DOI: https://doi.org/10.1182/blood-2006-10-054601
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
DOI: https://doi.org/10.1016/S1053-4296(03)00031-6
Vermeer MH, Geelen FA, van Haselen CW, van Voorst Vader PC, Geerts ML, van Vloten WA, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996; 132: 1304-1308.
DOI: https://doi.org/10.1001/archderm.1996.03890350042008
van Maldegem F, van Dijk R, Wormhoudt TA, Kluin PM, Willemze R, Cerroni L, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 2008; 112: 3355-3361.
DOI: https://doi.org/10.1182/blood-2008-01-132415
Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350: 213-215.
DOI: https://doi.org/10.1056/NEJMp038200
Wobser M, Voigt H, Eggert AO, Houben R, Kauczok CS, Brocker EB, et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 2007; 96: 1540-1543.
DOI: https://doi.org/10.1038/sj.bjc.6603762
Quereux G, Brocard A, Peuvrel L, Nguyen JM, Knol AC, Dreno B. Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma. Acta Derm Venereol 2011; 91: 562-567.
DOI: https://doi.org/10.2340/00015555-1113
Hoefnagel JJ, Vermeer MH, Jansen PM, Heule F, van Voorst Vader PC, Sanders CJ, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 2005; 141: 1139-1145.
DOI: https://doi.org/10.1001/archderm.141.9.1139
Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004; 31: 17-21.
DOI: https://doi.org/10.1053/j.seminoncol.2003.12.005
Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799-1806.
DOI: https://doi.org/10.1093/jnci/djr418
Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-1609.
DOI: https://doi.org/10.1182/blood-2008-04-152850
Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004; 22: 634-639.
DOI: https://doi.org/10.1200/JCO.2004.08.044
Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R, et al. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520-1526.
Published
How to Cite
License
Copyright (c) 2021 Stefanie Porkert, Pamela Mai, Constanze Jonak, Felix Weihsengruber, Klemens Rappersberger, Wolfgang Bauer, Ingrid Simonitsch-Klupp, Markus Raderer, Julia Valencak
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
